Publication:
Molecular Docking Studies and Synthesis of Amino-oxy-diarylquinoline Derivatives as Potent Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors

dc.contributor.authorMakarasen A.
dc.contributor.authorKuno M.
dc.contributor.authorPatnin S.
dc.contributor.authorReukngam N.
dc.contributor.authorKhlaychan P.
dc.contributor.authorDeeyohe S.
dc.contributor.authorIntachote P.
dc.contributor.authorSaimanee B.
dc.contributor.authorSengsai S.
dc.contributor.authorBoonsri P.
dc.contributor.authorChaivisuthangkura A.
dc.contributor.authorSirithana W.
dc.contributor.authorTechasakul S.
dc.contributor.authorDr.
dc.date.accessioned2021-04-05T03:04:46Z
dc.date.available2021-04-05T03:04:46Z
dc.date.issued2019
dc.date.issuedBE2562
dc.description.abstractIn this study, amino-oxy-diarylquinolines were designed using structure-guided molecular hybridization strategy and fusing of the pharmacophore templates of nevirapine (NVP), efavirenz (EFV), etravirine (ETV, TMC125) and rilpivirine (RPV, TMC278). The anti-HIV-1 reverse transcriptase (RT) activity was evaluated using standard ELISA method, and the cytotoxic activity was performed using MTT and XTT assays. The primary bioassay results indicated that 2-amino-4-oxy-diarylquinolines possess moderate inhibitory properties against HIV-1 RT. Molecular docking results showed that 2-amino-4-oxy-diarylquinolines 8(a-d) interacted with the Lys101 and His235 residue though hydrogen bonding and interacted with Tyr318 residue though π-π stacking in HIV-1 RT. Furthermore, 8a and 8d were the most potent anti-HIV agents among the designed and synthesized compounds, and their inhibition rates were 34.0% and 39.7% at 1 μM concentration. Interestingly, 8a was highly cytotoxicity against MOLT-3 (acute lymphoblastic leukemia), with an IC 50 of 4.63±0.62 μg/mL, which was similar with that in EFV and TMC278 (IC 50 7.76±0.37 and 1.57±0.20 μg/ml, respectively). Therefore, these analogs of the synthesized compounds can serve as excellent bases for the development of new anti-HIV-1 agents in the near future. © 2019 Georg Thieme Verlag. All rights reserved.
dc.format.mimetypeapplication/pdf
dc.identifier.citationDrug Research. Vol 69, No.12 (2019), p.671-682
dc.identifier.doi10.1055/a-0968-1150
dc.identifier.issn21949379
dc.identifier.other2-s2.0-85075814506
dc.identifier.urihttps://hdl.handle.net/20.500.14740/5695
dc.rights.holderScopus
dc.subject.other4 (2',6' dimethyl 4' cyanophenoxy) 2 (4" cyanophenyl)aminoquinoline
dc.subject.other4 (2',6' dimethyl 4' cyanophenoxy) 2 chloroquinoline
dc.subject.other4 (2',6' dimethyl 4' cyanophenoxy) 6 (4'' cyanophenyl)aminoquinoline
dc.subject.other4 (2',6' dimethyl 4' cyanophenoxy) 6 nitroquinoline
dc.subject.other4 (2',6' dimethyl 4' formylphenoxy) 2 (4'' cyanophenyl)aminoquinoline
dc.subject.other4 (2',6' dimethyl 4' formylphenoxy) 2 chloroquinoline
dc.subject.other4 (2',6' dimethyl 4' formylphenoxy) 6 (4" cyanophenyl)aminoquinoline
dc.subject.other4 (2',6' dimethyl 4' formylphenoxy) 6 nitroquinoline
dc.subject.other4 (4' cyanophenoxy) 2 (4" cyanophenyl)aminoquinoline
dc.subject.other4 (4' cyanophenoxy) 2 chloroquinoline
dc.subject.other4 (4' cyanophenoxy) 6 (4'' cyanophenyl)aminoquinoline
dc.subject.other4 (4' cyanophenoxy) 6 nitroquinoline
dc.subject.other4 (4' formylphenoxy) 2 (4" cyanophenyl)aminoquinoline
dc.subject.other4 (4' formylphenoxy) 2 chloroquinoline
dc.subject.other4 (4' formylphenoxy) 6 (4'' cyanophenyl)aminoquinoline
dc.subject.other4 (4' formylphenoxy) 6 nitroquinoline
dc.subject.otherAnti human immunodeficiency virus agent
dc.subject.otherAntileukemic agent
dc.subject.otherDoxorubicin
dc.subject.otherEfavirenz
dc.subject.otherEtoposide
dc.subject.otherEtravirine
dc.subject.otherNevirapine
dc.subject.otherNonnucleoside reverse transcriptase inhibitor
dc.subject.otherQuinoline derivative
dc.subject.otherRilpivirine
dc.subject.otherUnclassified drug
dc.subject.otherAnti human immunodeficiency virus agent
dc.subject.otherBenzoxazine derivative
dc.subject.otherEfavirenz
dc.subject.otherEtravirine
dc.subject.otherNevirapine
dc.subject.otherPyridazine derivative
dc.subject.otherQuinoline derivative
dc.subject.otherReverse transcriptase, Human immunodeficiency virus 1
dc.subject.otherRilpivirine
dc.subject.otherRNA directed DNA polymerase
dc.subject.otherRNA directed DNA polymerase inhibitor
dc.subject.otherAntileukemic activity
dc.subject.otherAntiviral activity
dc.subject.otherArticle
dc.subject.otherCell viability
dc.subject.otherComparative study
dc.subject.otherConcentration response
dc.subject.otherControlled study
dc.subject.otherCytotoxicity
dc.subject.otherDrug conformation
dc.subject.otherDrug cytotoxicity
dc.subject.otherDrug design
dc.subject.otherDrug potency
dc.subject.otherDrug protein binding
dc.subject.otherDrug structure
dc.subject.otherDrug synthesis
dc.subject.otherEnzyme inhibition
dc.subject.otherEnzyme linked immunosorbent assay
dc.subject.otherHuman
dc.subject.otherHuman cell
dc.subject.otherHuman immunodeficiency virus 1
dc.subject.otherHydrogen bond
dc.subject.otherIC50
dc.subject.otherMolecular docking
dc.subject.otherMolecular hybridization
dc.subject.otherMOLT-3 cell line
dc.subject.otherMRC-5 cell line
dc.subject.otherMTT assay
dc.subject.otherPharmacophore
dc.subject.otherStructure activity relation
dc.subject.otherXTT assay
dc.subject.otherChemistry
dc.subject.otherDrug effect
dc.subject.otherHuman immunodeficiency virus 1
dc.subject.otherHuman immunodeficiency virus infection
dc.subject.otherMetabolism
dc.subject.otherMolecular docking
dc.subject.otherTumor cell line
dc.subject.otherAnti-HIV Agents
dc.subject.otherBenzoxazines
dc.subject.otherCell Line, Tumor
dc.subject.otherDiarylquinolines
dc.subject.otherHIV Infections
dc.subject.otherHIV Reverse Transcriptase
dc.subject.otherHIV-1
dc.subject.otherHumans
dc.subject.otherMolecular Docking Simulation
dc.subject.otherNevirapine
dc.subject.otherPyridazines
dc.subject.otherReverse Transcriptase Inhibitors
dc.subject.otherRilpivirine
dc.titleMolecular Docking Studies and Synthesis of Amino-oxy-diarylquinoline Derivatives as Potent Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors
dc.typeArticle
dspace.entity.typePublication
swu.datasource.scopushttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85075814506&doi=10.1055%2fa-0968-1150&partnerID=40&md5=ff3b3822d05ec10d157aa7796904d722

Files